BD Diagnostics' Deal with Lonza Pushes BD Max Platform into Pharma QC Market

BD Diagnostics and Switzerland's Lonza have inked an agreement to develop and commercialize Lonza's microCompass molecular assays on the BD Max system for pharmaceutical quality-control testing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.